This has important implications for the subsequent development of HCC and screening strategy [29]. HBV is directly carcinogenic and may promote the development of HCC in the absence of cirrhosis, especially in populations where HBV may have been acquired at birth and in early childhood [31]. It has also become evident that high HBV viral loads may be linked to the development of HCC [32]. It is probable that a lower CD4 cell count, particularly in the context of HBV coinfection, is associated with a higher risk of HCC [33]. HIV coinfection also accelerates the

progression of HBV infection [34]. There is a large regional variation in the proportion of people with HIV who have previously been exposed to HBV (10–90%). Retrospective series suggest that HBV is responsible for a much smaller proportion of HCC compared to HCV in HIV-positive click here individuals [29,30]. HIV-positive LY2109761 HCC patients are younger and are more often HCV positive [30,35–37]. The majority of the HIV cohort has HCV and cirrhosis. The great majority of HIV-positive HCC patients are on HAART at diagnosis and consequently

they tend to be only moderately immunosuppressed [30,35]. There appears to be no significant difference between HIV-positive and -negative patients in the Barcelona Clinic Liver Cancer (BCLC) stage at presentation [35]. Most HCCs are identified with ultrasound scanning and AFP levels [30]. The degree of cirrhosis should be assessed prior to any definitive treatment using the Child–Pugh classification. HIV-positive HCC patients are more likely to have compensated liver disease (Child–Pugh A). A CT scan of the chest, abdomen and pelvis is required to exclude metastatic disease. Initial series in HIV-positive

individuals with HCC showed that the majority of patients were not being offered active treatment and that consequently outcome was poor [30]. Although more recent work has shown an improvement in the situation [35], others report that one-third of patients remain untreated and even in those with potentially curable disease, one-quarter receive less oxyclozanide effective treatment than is indicated [38]. When HIV patients are offered active treatment they have a similar survival to their HIV-negative counterparts [35,37,39–41]. Whether HIV status is itself related to survival remains uncertain. One series comparing 65 HIV-positive and 267 HIV-negative patients with HCC found that HIV status negatively influenced outcome in both treated and untreated patients [42], whilst HIV-associated HCC patients have a higher drop-out rate pre-transplantation and appear to have a more aggressive overall disease course [36].